Adagio Therapeutics announced its lead monoclonal antibody has neutralization activity against the Omicron variant of SARS-CoV-2.
Adagio is evaluating ADG20 in its global Phase 2/3 clinical trials for prevention and treatment of COVID-19.
Adagio is engaging with the FDA regarding protocol updates to its global Phase 2/3 clinical trials.
My price target is the $14.5 resistance.
Adagio is evaluating ADG20 in its global Phase 2/3 clinical trials for prevention and treatment of COVID-19.
Adagio is engaging with the FDA regarding protocol updates to its global Phase 2/3 clinical trials.
My price target is the $14.5 resistance.
BUY-SELL indicators: https://tradingindicators.store/ ASK FOR A FREE TRIAL!!!
How to install the indicators: https://www.youtube.com/watch?v=VsJ3V3Uczsk&t=2s&ab_channel=TradingIndicators
My Best Stock Picks: https://www.patreon.com/tradingindicators
How to install the indicators: https://www.youtube.com/watch?v=VsJ3V3Uczsk&t=2s&ab_channel=TradingIndicators
My Best Stock Picks: https://www.patreon.com/tradingindicators